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Abstract 
Disulfiram (DS), an anti-alcoholism drug, shows very strong cytotoxicity in many cancer types. 
However its clinical application in cancer treatment is limited by the very short half-life in the 
bloodstream. In this study, we developed a poly lactic-co-glycolic acid (PLGA)-encapsulated 
DS protecting DS from the degradation in the bloodstream. The newly developed DS-PLGA 
was characterized. The DS-PLGA has very satisfactory encapsulation efficiency, drug-loading 
content and controlled release rate in vitro. PLGA encapsulation extended the half-life of DS 
from shorter than 2 minutes to 7 hours in serum. In combination with copper, DS-PLGA 
significantly inhibited the liver cancer stem cell population. CI-isobologram showed a 
remarkable synergistic cytotoxicity between DS-PLGA and 5-FU or Sorafenib. It also 
demonstrated very promising anticancer efficacy and antimetastatic effect in liver cancer 
mouse model. Both DS and PLGA are FDA approved products for clinical application. Our 
study may lead to repositioning of DS into liver cancer treatment. 
 
Keywords 
Disulfiram, PLGA, liver cancer, cancer stem cells, drug repositioning, nano-technology, drug 
delivery 
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Background 
Primary liver cancer is the fifth most common neoplasm and the third most common cause of 
cancer-related death world wide.
1
 Hepatocellular carcinoma (HCC) accounts for 70% - 80% of 
cases of primary liver cancer.
2
 The incidence of HCC is high in Asia and increasing in the 
Western world in the past decade. Although the therapeutic outcomes in many cancers have 
been improved significantly, the prognosis of advanced HCC remains very dismal.
3
 
Chemoresistance and metastasis are the major hindrances for the treatment of advanced 
HCC. HCC cells are resistant to all currently available anticancer drugs. Sorafenib (Nexavar) is 
the sole drug showing marginal efficacy in HCC with only approximately 3 months 
improvement for overall survival.
4
 Therefore, development of efficacious chemotherapeutic 
drugs is of significant clinical importance for treatment of the advanced HCC. 
HCC is a highly heterogenic disease containing a small population of cancer stem-like cells 
(CSCs). HCC CSCs can be identified by detection of the expression of stem cell markers e.g. 
ALDH, CD133, CD90, CD44, EpCAM, and CD13.
5
 Previous studies suggest that CSCs are 
maintained by the hypoxic milieu,
6, 7
 quiescent and highly resistant to currently available 
chemotherapeutic agents. Conventional anticancer drugs eliminate bulk of cancer cells but 
could not eradicate CSCs, which become the source of the cancer recurrence and metastasis. 
Therefore, development of efficacious CSC-targeting drugs may improve the therapeutic 
outcomes of HCC. 
New drug development is a time and cash consuming procedure. This leads to the current 
interest in drug repositioning.
8
 Previous studies demonstrate that Disulfiram (DS), a 
commercially available anti-alcoholism drug,
9
 is highly cytotoxic to a wide range of cancer cell 
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lines
10-13
 and enhances conventional anticancer drug-induced apoptosis in colon, breast and 
brain cancer cell lines.
10, 14-16
 Importantly, DS is highly cancer specific and specifically inhibits 
the activity of aldehyde dehydrogenase (ALDH), a functional marker of CSCs and reactive 
oxygen species (ROS) scavenger
17, 18
 to eliminate CSCs. 
Although the anticancer activity of DS has been reported for almost 3 decades, its translation 
into clinical cancer treatment is severely limited by its very short half-life in the bloodstream.
19
 
The anticancer activity of DS is copper (Cu), zinc and some other divalent transitional metal 
elements dependent.
11, 20-22
 DS is quickly reduced to diethyldithiocarbamate (DDC), a strong 
chelator of copper(II). The reaction between DDC and Cu(II) generates ROS which are highly 
toxic to cancer cells. Due to the extremely short lifespan of ROS in human tissues,
23
 the 
extracellular ROS can target cancer cells only when the reaction takes place within the cancer 
tissues.
22, 24
 DDC-Cu, the final product of the DS and Cu reaction, can also penetrate into 
cancer cells and induce apoptosis.
22
 The sulfhydryl group of DDC is essential (Fig. 1A) for 
chelation of Cu(II) by DDC. The currently available oral version of DS is quickly reduced to 
DDC and the sulfhydryl group of DDC is promptly destroyed by glucuronidation, methylation 
and degradation in the bloodstream of the portal vein.
25
 This may introduce the discrepancy 
between the anticancer activity of DS in vitro, in vivo and in patients. In order to translate DS 
into cancer therapeutics, intact sulfhydryl group of DS or DDC must be protected in the 
bloodstream and delivered to cancer tissues where it reacts with Cu to generate ROS and 
form DDC-Cu (Fig. 1A). We previously showed that encapsulation of DS into liposome extends 
the half-life of DS and improves its in vivo anticancer efficacy in breast cancer mouse model.
6
 
The purpose of this study is to develop a long circulating poly lactic-co-glycolic acid (PLGA) 
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encapsulated DS (DS-PLGA) to achieve longer circulating time and improve the anticancer 
efficacy of DS. 
Methods 
Materials 
The HCC cell lines Huh7 and PLC/PRF/5 were purchased from ATCC (Middlesex, UK). DS, 
5-fluorouracil (5-FU), copper chloride (CuCl2), copper gluconate (CuGlu), poly 
lactic-co-glycolic acid (PLGA), Poly(vinyl acetate), cyanomethyl diphenylcarbamodithioate 
(PVA), dichloromethane, poly-2-hydroxyethyl methacrylate (poly-HEMA) and bovine serum 
albumin (BSA) were purchased from Sigma (Dorset, UK). DMEM medium and fetal calf serum 
(FCS) were supplied by Lonza (Wokingham, UK). Ki67 and BAX antibodies were purchased 
from Cell Signaling (Danvers, MA, USA). NFkBp65 and ALDH1 antibodies were from AbCam. 
Sorafenib was from BioVision (CA, USA). Cell culture inserts were purchased from Fisher 
(Loughborough, UK). Lipo-DS was provided by Prof Xing Tang (Shenyang Pharmaceutical 
University, China). 
Preparation and characterization of DS-PLGA nanoparticles 
The DS loaded nanoparticles were prepared using an emulsion–solvent evaporation method. 
PLGA (200 mg) and DS (20, 40, 50, 100 or 150mg) were dissolved in 10mL of 
dichloromethane, and then mixed with 20mL of 2.5% PVA aqueous solution. This mixture was 
homogenized for 1 min by vortex and then sonicated using a microtip probe sonicator set at 70% 
power output (XL 2002 Sonicator® ultrasonic liquid processor) for 3, 4 or 5 min to produce the 
oil-in-water emulsion. The organic phase was evaporated for 5h at room temperature. The 
nanoparticles were recovered by centrifugation (10,000 rpm, 20 min, Hitachi). The 
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nanoparticles were washed twice with water. The purified nanoparticles were freeze-dried in 5% 
sucrose. 
The size distribution and zeta potential of DS-PLGA were measured by DLS using a Zetasizer 
(ZS90, Malvern, U.K.) with a scatter angle of 90° at 25°C. The morphology of nanoparticles 
was observed by scanning electron microscopy (SEM) (JEOL JSM T330A). A drop of the 
nanoparticle suspension was placed on a metallic surface. After drying under vacuum, the 
sample was coated with a gold layer. 
Measurement of encapsulation efficiency, drug loading content, cumulative release and 
the in vitro half-life of DS-PLGA 
The amount of non-entrapped DS was determined using HPLC by UV detection set at 275 nm 
(SHIMADZU LC-20). The mobile phase was a mixture of methanol:water (70:30%) and the 
flow rate was set at 1 ml/min. Separation was achieved using a Phenomenex C18 column 
(250mm  4.6 mm, 5m). The amount of DS entrapped in the nanoparticles was determined 
after their dissolution in dichloromethane. After evaporation of dichloromethane at room 
temperature, DS was dissolved in pure ethanol. The supernatants were passed through a 
membrane filter (pore size 0.22 m, Millipore) before HPLC measurements. The cumulative 
release profile of DS-PLGA was measured in 0.1 M phosphate buffer solution (PBS, pH 7.4) 
with 0.5% Tween 80 at 37°C. In brief, 10mg DS-PLGA was suspended in 25ml PBS-Tween80 
solution with continuously shaking (100 rpm min
-1
) at 37°C. At indicated time intervals, 500 l 
of the release media were collected and centrifuged at 14,000 rpm for 10 min at room 
temperature to remove the PLGA nanoparticles with unreleased DS. The DS concentrations in 
the supernatant were measured using HPLC and equal volume of fresh media were 
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replenished. The drug loading content (DLC) and encapsulation efficiency (EE) of DS in the 
PLGA nanoparticles were calculated using the following equations. 
DLC (%) = Weight of DS in PLGA/Weight of the whole DS-PLGA  100% 
EE (%) = (Weight of total DS – Weight of free DS)/ Weight of total DS  100% 
To examine the half-life of DS in vitro, free DS or DS-PLGA (100 l at a concentration of 3 
mg/ml) was added into an eppendorf tube containing 300 l of horse serum with shaking at 
37°C. The eppendorf tubes were collected and protein precipitated by adding 300 l of 
absolute methanol at different time intervals. The PLGA nanoparticles with unreleased DS 
were removed by centrifugation at 14,000 rpm for 10 min at room temperature. The DS in the 
supernatant was determined by HPLC measurement. 
In vitro cytotoxicity of DS-PLGA to HCC cells 
The PLC/PRF/5 and Huh7 HCC cell lines were cultured in DMEM supplemented with 10% 
FCS, 50 units/ml penicillin, 50 g/ml streptomycin. For in vitro cytotoxicity assay, the overnight 
cultured cells (5,000/well) in 96-well flat-bottomed microtiter plates were exposed to drugs for 
72 h in normoxic or hypoxic condition and subjected to a standard MTT assay.
16
 
Analysis of the combinational effect of 5-FU + DS-PLGA/Cu and Sorafenib + DS-PLGA/Cu 
The HCC cells were cultured at 5,000 cells/well in 96-well plates overnight and then exposed 
to various concentrations of 5-FU, Sorafenib, DS-PLGA/Cu1µM, 5-FU or Sorafenib in 
combination with DS-PLGA/Cu1µM at a constant ratio of 5-FU:DS-PLGA and 
Sorafenib:DS-PLGA = 1000:1 and 100:1 respectively. The cells were exposed to different drug 
combinations for 72 hours and subjected to MTT analysis.
16
 The IC50s from one and 
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two-drug-treated cells were determined. The combinational cytotoxicity was analyzed by 
CI-isobologram program using CalcuSyn software (Biosoft, Cambridge, UK).
26
 The 
combination index (CI) was determined by mutually exclusive equations. 
Flow cytometric detection of ALDH activity and CD133 expression 
The ALDH positive population was detected by ALDEFLUOR kit (StemCell Tech., Durham, 
NC, USA) following the supplier’s instruction. The cells (2.5 × 10
5
) were analyzed after stained 
in ALDH substrate containing assay buffer for 30 min at 37°C. Diethylaminobenzaldehyde 
(DEAB), a specific ALDH inhibitor, treated cells were used as a positive control. 
To detect the expression of CD133 positive cells, the cells (2.5 × 10
5
) were incubated with 
CD133 antibody (BD Pharmingen, Oxford, UK) for 30 min at 4°C. Unbound antibodies were 
washed off with 2% FCS HBSS (Sigma). After staining for no longer than 1 hour, the positively 
stained population (10,000 events) was detected using a BD Accuri
TM
 C6 flow cytometer 
(Becton Dickinson, Franklin Lakes, NJ, USA) with 488-nm blue laser and standard FITC 
530/30 nm bandpass filter. 
Flow cytometric detection of apoptosis 
DNA content was used to detect the apoptotic cells. Briefly, cells (1x10
6
) were exposed to 
drugs and harvested by trypsinisation. The cells were fixed in 70% ethanol and then incubated 
with RNase A (100 g/ml) and propidium iodide (2.5 mg/ml) for 30 min. The DNA content data 
from 10,000 cells in each sample was collected by a BD Accuri
TM
 C6 flow cytometer and 
analysed using a CellQuest software (BD Biosciences, Oxford, UK). 
Clonogenic assay 
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The overnight cultured cells (5×10
4
) were exposed to DS-PLGA (50 nM), CuCl2 (1 M), 
DS-PLGA (50 nM) plus CuCl2 (1 M), 5-FU (200 M) or sorafenib (20 M) for 6h. The cells 
were collected and sub-cultured in 6-well plates containing drug-free medium at a cell density 
of 2.5  10
3
/well. After 10 days culture, the clonogenic cells were determined by counting the 
colonies containing at least 50 cells. 
In vitro HCC sphere cell culture 
To culture the HCC spheres, cells were cultured in poly-HEMA coated ultra-low adherence 
flasks or plates to prevent cell adhesion. The spheres were cultured, at a density of 5,000 
cells/ml, in stem cell culture medium [SCM, serum-free DMEM-F12 supplemented with B27 
(Invitrogen, Paisley, UK), 20 ng/ml epidermal growth factor (EGF, Sigma), 10 ng/ml basic 
fibroblasts growth factor (b-FGF, R & D System, Abingdon, UK). After 7 days culture, the 
spheres were subjected to different treatments. 
In vitro migration and invasion assay 
Cell invasion and migration assays were performed using cell culture inserts (Millipore) coated 
with or without Matrigel (BD Bioscience, Bedford, MA, USA), respectively. Cells (5 × 10
4
) were 
resuspended in 200 μl serum-free DMEM and placed in upper chamber of the insert. The 
lower chamber was filled with medium containing 10% FCS. After 48 hours incubation at 37°C, 
migrated cells were fixed by methanol and stained in 0.5% crystal violet. Cells in six random 
microscopic fields were counted. 
HCC xenograft and in vivo metastasis experiments 
Five-week-old female BALB/c Nu/Nu athymic nude mice (Biotechology & Cell Biology 
Shanghai, China) were housed under pathogen-free conditions according to the Third Military 
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Medical University (TMMU) animal care guidelines and the animal experiments were reviewed 
and approved by the Ethical Committee of TMMU. PLC/PRF/5 cells (5×10
5
) were 
subcutaneously injected at one front flank of the mice. When the tumor volume (V) reached 
~200mm
3
, the tumor bearing mice were randomly subdivided into 8 groups (8 mice/group): 1. 
Control: No treatment; 2. Copper gluconate (CuGlu) 6mg/kg p.o.; 3. Empty PLGA i.v.; 4. Free 
DS 10mg/kg p.o. + CuGlu 6mg/kg p.o.; 5. DS-PLGA 2.5mg/kg i.v. + CuGlu 6mg/kg p.o.; 6. 
DS-PLGA 5mg/kg i.v. + CuGlu 6mg/kg p.o.; 7. DS-PLGA 10mg/kg i.v. + CuGlu 6mg/kg p.o.; 8. 
DS-Lipo 10mg/kg i.v. + CuGlu 6mg/kg p.o. We chose copper gluconate for in vivo study 
because it showed similar effect in vitro (Table 2) and is more tolerable by animal. The animals 
were treated 3 times/week for successive 3 weeks. The xenograft size was recorded trice per 
week. The tumor volume was calculated by the following formula: V =(L×W
2
)×0.5, where L is 
the length and W is the width of the tumor. After 3 weeks, the animals were sacrificed. The 
tumors were removed, photographed and subjected to further analysis.  
The in vivo lung metastasis mouse model was established by injecting 5x10
6
 single-cell 
suspension of PL /PRF/5 cells (in 200 l of PBS) into the tail vein. After 2 weeks, the mice 
were treated 3 times/week with 10mg/kg DS-PLGA i.v. and CuGlu 6mg/kg p.o. for 4 
successive weeks. The mice were sacrificed two days after the last treatment. The lungs were 
removed and formalin-fixed for paraffin embedment and H&E staining. 
Immunohistochemistry and H&E staining 
The sections from paraffin embedded tumor and normal tissues were stained with primary 
antibodies (Ki67, 1:200; BAX, 1:200; NFkBp65, 1:200; ALDH1, 1:200) then biotinylated 
secondary antibody and followed by incubation in ABC reagent (DAKO Labs, Cambridgeshire, 
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UK). For H&E staining, the paraffin-embedded sample slides were stained with hematoxylin 
and eosin and the slides were mounted with coverslips using Permount (Fisher Sci, 
Loughborough, UK). 
Statistical analysis 
The statistical significance of treatment outcomes was assessed using Student's t-test and 
one-way ANOVA; p <0.05 was considered statistically significant in all analyses. 
Results 
Physicochemical characterization of DS loaded PLGA nanoparticles 
The influence of PLGA:DS ratio and sonication/homogenizing time on the EE, DLC and 
nanoparticle size were examined. The PLGA:DS ratio of 2:1 (w/w) and 4 min of sonication 
provided us with the most optimum nano-characteristics with most narrow size (131.8±6.9 and 
136.2±6.2 nm) and satisfactory zeta potential (-22.3±0.8 and -21.7±0.96mV) distribution 
between the empty and DS loaded PLGA nanoparticles (Table 1 and Suppl Table S1, S2). The 
SEM image showed that the DS-PLGA was in analogous spherical shapes (Fig. 1B). 
DS-PLGA showed high EE (78.92±2.16％) with satisfactory DLC (27.67±3.47%). 
To determine the stability and release of DS in DS-PLGA, the DS-PLGA was incubated in 1%, 
5% and 10% BSA solutions at 37°C. The particle size was increased in a time and BSA 
concentration-dependent manner (Fig. 1C). The zeta potential of the DS-PLGA was also 
examined after 24 hours incubation in BSA solution. At a physiological concentration of BSA 
(5%), the DS-PLGA maintained a satisfactory particle size (162 nm) and zeta potential (-15.8 
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mV) for at least 8 and 24 hours, respectively (Fig. 1D). The DS-PLGA showed very good 
dispersibility. 
In vitro cumulative release and half-life of DS in serum 
The cumulative drug release was performed over a period of 7 days in a 0.5% Tween 80 PBS 
solution (pH 7.4) at 37°C. The DS concentrations at different time lengths were examined. 
Results demonstrate a very steady and sustained release of DS over 7 days. Around 20% of 
DS was released within 24 hours and reached a 40% release at day 4, which was maintained 
until day 7 (Fig. 1E). To determine the half-life of DS in vitro, the free DS and DS-PLGA (100 
g/ml) were dispersed into horse serum at 37°C. The free DS was rapidly degraded to 
undetectable levels within 30 seconds (Fig. 1F). In contrast, DS commenced its release from 
PLGA at 2 min, equivalent to 34.23 ± 3.38% of the initial drug loading and peaked in 4 min at 
51.27±5.98%. The controlled release was last for at least 24 hours. The half-life of DS-PLGA 
in serum (7 hours) is significantly longer than that of free DS (Fig. 1G).  
In vitro cytotoxicity of DS-PLGA NPs in HCC cells 
The cytotoxicity of DS-PLGA and free DS in PLC/PRF/5 and Huh7 HCC cell lines was 
compared by MTT assay. CuCl2 (1 M) was supplemented in all the experiments. The in vitro 
cytotoxicity of DS-PLGA is slightly lower than that of the free DS but no significant difference 
between the IC50s of DS-PLGA (Huh7, 30.69 ± 3.83 nM; PLC/PRF/5, 49.33 ± 4.11 nM) and 
free DS (Huh7, 25.34 ± 3.21; PLC, 45.25 ± 3.52 nM) (p>0.05) (Fig. 2A, B). After exposure to 
DS-PLGA (50 nM) and CuCl2 (1 M) for 4 hours, the apoptotic cells (sub-G1 population) were 
identified by DNA content assay using flow cytometry analysis. Background levels of 
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spontaneous apoptotic cells were detected in untreated (2.47% and 3.31%) and PLGA empty 
nanoparticles plus CuCl2 treated (2.58% and 3.14%) Huh7 and PLC/PRF/5 cell lines 
respectively. In contrast, massive apoptotic cells (15.68% and 44.47%) were detected in 
DS-PLGA/CuCl2 treated Huh7 and PLC/PRF/5 cell lines, respectively (Fig. 2C).  
Hypoxia induced CSC traits and resistance to conventional anticancer drugs 
To determine the effect of hypoxia on CSC population, two CSC markers, ALDH and CD133, 
were examined in hypoxia and normoxia cultured HCC cell lines. The enhanced ALDH activity 
and elevated expression of CD133 indicated that the CSC population in PLC/PRF/5 and Huh7 
cell lines was significantly enlarged by hypoxic environment (Fig. 3A and B). The specificity of 
ALDH detection was confirmed by DEAB inhibition (Fig. 3C). Furthermore, we examined the 
chemosensitivity of HCC cell lines at hypoxic condition. When cultured at 1% O2, the HCC cell 
lines were significantly resistant to 5-FU and Sorafenib (Fig. 3D - F).  
DS-PLGA inhibited hypoxia-induced CSCs and synergistically enhanced cytotoxicity of 
5-FU and Sorafenib 
Incubation of HCC cells with DS-PLGA (20 nM) and CuCl2 (1 M) for 24h significantly reduced 
the ALDH
+
 and CD133
+
 cell population in PLC/PRF/5 and Huh7 cell lines suggesting the 
sufficient inhibitory effect of DS-PLGA on hypoxia-induced CSCs. In contrast, 5-FU (200 M), 
Sorafenib (20 M), Cu or DS-PLGA alone had no effect on CSC marker expression (Fig. 4A). 
Furthermore, the combinational effect of DS-PLGA/Cu and 5-FU or Sorafenib was examined 
using CI-isobologram assay. In combination with DS-PLGA, the in vitro cytotoxicity of 5-FU 
and Sorafenib was significantly enhanced. CI-isobologram analysis indicates very significant 
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synergistic combinational effect between 5-FU, Sorafenib and DS-PLGA/Cu in a wide range of 
IC values (IC50 – IC90) (Table 2, Fig S1, S2).  
DS-PLGA inhibited expression of CSC markers in spheroid culture and eradicated 
sphere-forming and clonogenic abilities. 
CSCs can form spheres in stem cell culture conditions. Sphere-forming ability is widely 
accepted as a golden standard for in vitro analysis of stemness of CSCs.
27
 The effect of 
different treatments on sphere-forming ability was examined. A significantly higher percentage 
of ALDH and CD133 positive CSC population was detected in spheroid cells (Fig. 4B). The 
ALDH and CD133 positive CSC population in the spheres was significantly reduced after 
exposure to DS-PLGA (20 nM) and Cu (1 M) for 4 hours but not affected by other treatments. 
The sphere-forming ability was completely abolished after exposure to DS-PLGA (20 nM) plus 
Cu (1 M) for 6 hours. No inhibiting effect was observed in 5-FU and Sorafenib treated cells 
(Fig. 4C and D). The DS-PLGA/Cu treated HCC CSCs underwent apoptosis (Fig. 4E and F). 
We next performed clonogenic assay, a traditional method to determine the self-renewal 
capacity, cancer cell regeneration and CSC traits,
28
 to examine the ability of DS-PLGA/Cu to 
induce the ‘reproductive death’ in HCC cell lines. The monolayer-cultured PLC/PRF/5 and 
Huh7 cells were exposed to 5-FU (200 M), Sorafenib (20 M), CuCl2 (1 M), DS-PLGA (50 
nM) or DS-PLGA (50 nM) plus CuCl2 (1 M) for 6h. The treated cells were collected and 
cultured in 6-well plates containing drug-free medium at a cell density of 500 cells/well for 
another 10 days. There was no significant difference in colony numbers when the control 
group was compared with 5-FU, Sorafenib and CuCl2 treated groups. In contrast, the colonies 
in DS-PLGA/Cu treated group were completely eradicated in both cell lines (Fig. 4G and H).  
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DS-PLGA blocked migration and invasion ability of hypoxic and sphere-cultured cells in 
vitro 
CSCs have high metastatic ability, another key event responsible for the very poor prognosis 
of the advanced HCC patients. Because DS-PLGA/Cu shows very strong inhibiting effect on 
CSC traits in HCC cell lines, we further examined its effect on cell migration and invasion in 
vitro. The hypoxia (Fig. 5A and B) and CSC (C and D) induced migration and invasion was 
significantly inhibited by DS-PLGA/Cu at an extremely low concentration (5 nM) which is only 
1/8 to 1/10 of the IC50 concentrations for Huh7 and PLC/PRF/5 respectively. At this 
concentration, no cytotoxicity was observed in both cell lines. 
In vivo anti-HCC efficacy of DS-PLGA in mouse xenografts 
To assess anti-tumor activity in vivo, 2.5mg/kg, 5mg/kg and 10mg/kg DS-PLGA were 
intravenously injected into the tail veins of the HCC xenograft bearing mice. In comparison 
with the control group, 10 mg/kg DS-PLGA significantly inhibited tumor size and tumor weight 
(Fig. 6A and B). An equivalent oral dose of DS/Cu or Lipo-DS i.v./oral-Cu, had no effect on the 
xenografts. This result indicates that the PLGA encapsulation protected DS from degradation 
in the bloodstream and delivered the intact DS to cancer tissues. DS-PLGA/Cu treatment 
inhibited the expression of NFB p65 and ALDH in the HCC xenografts (Fig. 6C). No 
significant mouse body weight difference between the control and treated groups and no 
cytotoxic effect was observed in the vital organs e.g. lung, liver and kidney (Fig. 6D and E). 
DS-PLGA and copper blocks HCC lung metastasis in vivo 
The very encouraging in vitro anti-migration and invasion data prompted us to examine the 
anti-metastatic effect of DS-PLGA/Cu in vivo. The lung metastasis of the tail vein injected HCC 
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cells was completely blocked by combinational application of DS-PLGA and CuGlu (Fig. 7). 
Cancer nodules and micro-metastasis were observed in the control group but not in the 
treated animals. All the in vivo experiments were performed with the guidelines approved by 
the Institutional Animal Care and Use Committee of the Fourth Military Medical University. 
Discussion 
Only 5-25% of new oncology drugs in clinical development are actually reaching the market.
8, 
29
 This has led to an increasing appreciation of the potential of repurposing known drugs for 
cancer treatment. DS is highly cytotoxic in several types of cancer cells in vitro,
6, 10, 15, 16, 30-32
 
whereas oral administration of free DS does not inhibit tumor growth in vivo.
33
 Recent 
publication suggests that the intact sulfhydryl group is essential for the anticancer function of 
DS.
22, 24
 The degradation of DS in the bloodstream destroys the sulfhydryl group making DS 
lose its cancer targeting ability. The degradation of DS in the serum kinetically results from a 
covalent interaction of this drug with the free sulfhydryl of serum albumin. The half-life of DS 
pH 7.4 is 1 – 1.5 minutes.
19, 34, 35
 
36
 
37
 This may introduce the discrepancy between the 
anticancer activities in vitro, in vivo and in clinic (ClinicalTrials.gov: NCT00256230, 
NCT00742911, NCT01118741). Nanomedicine can protect and deliver drugs in the 
bloodstream.
38
 The in vivo anticancer efficacy of DS can be improved by liposomal 
encapsulation (half-life ~25 min).
6, 33
 In this study, we successfully extended the half-life of DS 
to ~7 hours by encapsulation of DS into PLGA (Fig. 1G). We achieved very satisfied EE, DLC, 
nano-particle size and dispersibility (Table 1). The DS encapsulated nano-particles are stable 
in physiological concentrations of BSA and the release of DS was steadily controlled at 37C. 
Importantly, after 8 hours incubation, the DS concentration in the serum still remained at ~40 
M (12 g/ml, Fig. 1F) which is markedly higher than the IC50s of DS in a wide range of cancer 
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types (~50 – 500 nM).
6, 10, 15, 16, 30-32
 DS-PLGA/Cu induced HCC cell apoptosis and the in vitro 
cytotoxicity of DS-PLGA/Cu was comparable to the free DS (Fig. 2A and B). Therefore, 
nanomedicine may be a novel strategy for protection of the sulfhydryl group in DS and 
translation of DS into cancer treatment. 
HCC is resistant to all currently available anticancer drugs with only very marginal response to 
Sorafenib.
4
 It has been widely accepted that CSCs display significant resistance to cytotoxic 
drugs with different resistant mechanisms.
39
 Hypoxia is a common feature of HCC. The 
median partial pressure of O2 in HCC is 6 mmHg as compared to 30 mmHg in normal liver 
tissues.
40
 Emerging evidence suggests that hypoxia plays pivotal roles in chemoresistance.
41
 
The hypoxic condition in the stem cell niche is essential for maintaining the stemness in 
CSCs.
42
 Therefore inhibition of hypoxia-induced CSCs may sensitize cancer cells to 
conventional anticancer drugs. Previous studies indicate that DS targets CSCs and sensitizes 
several types of cancers to conventional anticancer drugs.
6, 10, 16, 30, 32, 43, 44
 Our results 
demonstrated that hypoxia increased CSC population in HCC cell lines. The hypoxic cells 
were highly resistant to 5-FU and Sorafenib (Fig. 3). DS-PLGA/Cu synergistically enhanced 
the cytotoxicity of 5-FU and Sorafenib in HCC cells (Table 2 and Fig. S1, S2). At a very low 
concentration (20 nM), DS-PLGA/Cu significantly inhibited the ALDH and CD133 positive CSC 
population in both hypoxia-induced and spheroid cultured HCC cell lines (Fig. 4A and B). The 
sphere forming and clonogenic ability in HCC cell lines was completely abolished by very low 
concentration of DS-PLGA/Cu. In contrast, 5-FU and sorafenib had no effect on CSC 
population. DS-PLGA/Cu also very strongly in vivo inhibited NFB and ALDH activity which 
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are highly responsible for the stemness of CSCs
6, 16, 30
 and efficaciously targeted HCC 
xenografts at an equivalent to 1/5 of the human antialcoholism dose. The effect of 
DS-PLGA/Cu on HCC xenografts was dose dependent (Fig. 6A and B). In consistence with 
our previous study,
6
 no toxicity was observed in the vital organs of the DS-PLGA/Cu treated 
animals (Fig. 6E). 
HCC has been shown the hypoxia-induced epithelial-to-mesenchymal transition (EMT), a 
typical character of CSCs involving in metastasis.
45
 
46
 Liver transplantation is carried out to 
treat HCC, especially in the early stage. However, due to the extrahepatic organ 
micrometastasis, the incidence of postoperative recurrence and metastasis is very high (60 – 
100%).
47
 Lung remains the most frequent site for HCC metastasis. At the time of diagnosis, 
most patients have multiple pulmonary or systemic metastasis.
48
 There are still no effective 
systemic therapies available for the metastatic HCC. Therefore development of a drug with 
anti-metastatic effect will improve HCC treatment.
49, 50
 DS-PLGA/Cu showed very strong 
anti-metastatic effect on HCC in vitro (Fig. 5) and in vivo (Fig. 7), highly in line with our in vivo 
metastatic lung cancer data (unpublished data). Therefore, DS-PLGA is potentially an effective 
anti-metastatic drug for HCC treatment.  
In conclusion, we showed that the DS-PLGA has very satisfactory EE, DLC, in vitro controlled 
release and half-life. DS-PLGA and copper showed very strong inhibiting effect on CSCs and 
synergistic cytotoxicity with 5-FU and Sorafenib. It also manifests very promising anticancer 
efficacy and anti-metastatic activity in HCC mouse model. Our results suggest that 
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nano-controlled delivery system may lead to fast translation of DS into liver cancer treatment.   
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Figure Legends 
Figure 1. In vitro characterization of DS-PLGA. A. The scheme of DS metabolism and 
reaction with copper(II). B. Scanning electron micrographs of PLGA and DS-encapsulated 
PLGA (DS-PLGA). C. The influence of serum concentration on the size of DS-PLGA. D. The 
influence of serum concentration on Zeta potential. E. In vitro release profiles of DS. F. In vitro 
half-life of DS in horse serum. G. The in vitro half-life of free DS and DS-PLGA in horse serum. 
** p<0.01 
Figure 2. In vitro cytotoxicity of DS-PLGA in HCC cell lines. The PLC/PRF/5 (A) and Huh7 
(B) HCC cell lines were exposed to drugs for 72h and subjected to typical MTT cytotoxicity 
assay. n=3, the vertical bars represent SD. (C) PLC/PRF/5 and Huh7 cell lines were subjected 
to different treatments for 4h. The DNA contents were measured by flow cytometry analysis. 
Typical histograms are presented. N=3; ** p<0.01 
Figure 3. Hypoxia induced expression of CSC marker and chemoresistance in HCC 
cells. A and B. PLC/PRF/5 and Huh7 cells were cultured in either normoxic or hypoxic 
condition for 5 days. The ALDH activity and expression of CD133 were examined by flow 
cytometry. C. The specificity of ALDH detection was confirmed by DEAB inhibition. D – F. After 
72h exposure, the cytotoxicity of 5-FU and Sorafenib was determined in HCC cell lines 
cultured at normoxic and hypoxic conditions. **p<0.01 
Figure 4. DS-PLGA inhibited hypoxia-induced CSC marker expression, eradicated 
sphere forming ability and clonogenicity in HCC cell lines A. Percentage of ALDH and 
CD133 positive cells. The HCC cells were cultured at hypoxic condition for 5 days and 
subjected to different treatments for 4 hours (DS represents DS-PLGA). B. After exposure of 
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sphere cells to different drugs for 24 hours, the ALDH and CD133 positive population was 
examined by flow cytometry (DS represents DS-PLGA). C and D. DS-PLGA/Cu blocked the 
sphere-forming ability in HCC cell. E and F. DS-PLGA/Cu induced apoptosis in sphere cells. G 
and H. DS-PLGA/Cu eradicated clonogenicity in HCC cell lines. n=3; **p<0.01 
Figure 5. DS-PLGA inhibited migration and invasion ability in hypoxia- and 
sphere-cultured HCC cells. DS-PLGA/Cu inhibited migration and invasion of hypoxic HCC 
cells (A and B). After 7 days hypoxic culture, the HCC cells were subcultured in a transwell 
containing different chemicals at hypoxic condition for 48 hours (DS represents DS-PLGA). C 
and D. DS-PLGA/CuCl2 inhibited migration and invasion of HCC CSCs. After 7 days sphere 
culture, the HCC cells were subcultured in a transwell containing different chemicals at 
hypoxic condition for 48 hours. n=3, ** p<0.01.  
Figure 6. DS-PLGA + Cu inhibited the growth of HCC derived xenografts and the in vivo 
effect on different biological pathways. A. The growth curves of tumor size. The drugs were 
administered 3 times/week for successive 3 weeks. B. The weight of tumors at the end of 
experiment. Control: no treatment, Cu: CuGlu p.o., Empty NPs: Empty PLGA i.v., Free DS + 
Cu: DS p.o. + CuGlu p.o.; PLGA + Cu: DS-PLGA i.v. + CuGlu p.o., Lipo DS + Cu: Liposome 
DS i.v. + CuGlu p.o. C. The effect of DS-PLGA (10mg/kg) plus CuGlu (6mg/kg) on the protein 
expression of Ki67, BAX, NFB and ALDH in HCC xenografts (×400 magnification). D. The 
body weight changes during the experimental period. E. Representative histo-pathological 
images of lung, liver and kidney in DS-PLGA plus CuGlu treated mice. (H&E staining,  400 
magnification). 
Figure 7. DS-PLGA + CuGlu blocked lung metastasis. A. The images of lung metastatic 
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nodules (black arrows). B. The cancer nodule number in lung. C. Representative H&E staining 
microscopic images showing the histology of metastatic nodules in mouse lung.  
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Table 1. Physicochemical parameters of PLGA and DS loaded PLGA nanoparticles   
Nanoparticles 
Drug Loading 
Content (%) 
Encapsulation 
Efficiency (%) 
Size (nm) 
Zeta potential 
(mV) 
Empty PLGA  - - 131.8±6.9 22.3±0.8 
DS-PLGA 27.67±3.47 78.92±2.16 136.2±6.2 21.7±0.96 
 
 
 
 
Table 2. Cytotoxicity of 5-FU, Sorafenib, DS-PLGA, 5-FU/DS-PLGA and 
Sorafenib/DS-PLGA in HCC cell lines 
  Huh7 PLC/PRF/5 
IC50s 
  5-FU (μM) 103.26 (6.21) 122.84 (8.14) 
Sorafenib (μM) 22.88 (1.26) 30.89 (2.61) 
DS-PLGA (nM) + CuCl2  30.69 (3.83) 49.33 (4.11) 
DS-PLGA (nM) + CuGlu  38.6 (5.88) 35.5 (7.98) 
5-FU (μM)/DS-PLGA (nM) + CuCl2 18.74 (1.09) /18.74 (1.09) 27.56 (1.09)/27.56 (1.09) 
Sorafenib (μM)/DS-PLGA (nM) + CuCl2 2.21 (0.19)/22.07 (1.88) 3.08 (0.12)/30.77 (1.17) 
CI Values 
  
5-FU/DS 
IC50 0.001 0.003 
IC75 0.001 0.003 
IC90 0.002 0.002 
Sorafenib/DS 
IC50 0.006 0.051 
IC75 0.010 0.094 
IC90 0.018 0.178 
The figures are IC50s and CI values respectively. The numbers in the parenthesis are the SD. 
N=3. CI values: 0.9 –1.1  additive effect; 0.8–0.9  slight synergism; 0.6–0.8  moderate 
synergism; 0.4–0.6  synergism; 0.2–0.4 strong synergism. Both CuCl2 and CuGlu are 1 μM. 
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Graphical Abstract 
Disulfiram (DS), an antialcoholism drug, shows very strong anticancer activity in 
vitro but no encouraging clinical data published. This discrepancy is caused by 
the very short (< 4 min) half-life of DS in the bloodstream. 
DS is a strong divalent copper(II) chelator. The reaction between DS and 
copper(II) generates reactive oxygen species (ROS) which target cancer cells. In 
this reaction, the intact sulfhydryl groups in DS molecule are essential. After oral 
administration of DS, the sulfhydryl groups are promptly methylated or 
glucuronidated in portal vein and liver. The methylated and glucuronidated DS 
completely loses its anticancer activity. In this study, we developed an 
intravenously applicable long-circulating PLGA encapsulated DS (DS-PLGA). 
DS-PLGA extends the half-life of DS to 7 hours and delivers intact DS to cancer 
tissues where it reacts with copper to generate ROS targeting cancer cells.  
 
